Patents by Inventor DENGJIAO MA

DENGJIAO MA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human coagulation factor light chain protein and use of the same
    Patent number: 9782461
    Abstract: In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 10, 2017
    Assignee: Chengdu Sourcebio Limited-Liability Company
    Inventors: Xu Song, Ling Li, Jinwu Chen, Dongsheng Liao, Dengjiao Ma
  • HUMAN COAGULATION FACTOR LIGHT CHAIN PROTEIN AND USE OF THE SAME
    Publication number: 20160106818
    Abstract: In the invention, the minimum inhibitory concentrations of human coagulation factor light-chain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity and the inhibiting effect of the human coagulation factor light-chain proteins against different Gram-negative bacteria is detected with the in vivo antibacterial activity. It has been shown that human coagulation factor light-chain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by mass spectrometry and silver staining that human coagulation factor light-chain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 21, 2016
    Applicant: CHENGDU SOURCEBIO LIMITED-LIABILITY COMPANY
    Inventors: XU SONG, LING LI, JINWU CHEN, DONGSHENG LIAO, DENGJIAO MA